UroVysionTM testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer

Jared M. Whitson, Anna B. Berry, Peter R. Carroll, Badrinath R. Konety

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint Dive into the research topics of 'UroVysion<sup>TM</sup> testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences